Structure Therapeutics financials
$32.69−6.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$186.8M | -$158.2M | -$102.8M |
| Net income | -$141.2M | -$122.5M | -$89.6M |
| Net margin | — | — | — |
| Diluted EPS | $-0.80 | $-0.78 | $-0.81 |
| EBITDA | -$185.5M | -$157.2M | -$102.5M |
| Operating cash flow | -$222.2M | -$116.6M | -$79.5M |
| Free cash flow | -$225.8M | -$117.9M | -$81.7M |
| Diluted shares | 177.6M | 157.9M | 110.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $799.6M | $169.5M | $129.8M |
| Short-term investments | $646.6M | $714.0M | $337.5M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $1.58B | $903.3M | $482.0M |
| Total liabilities | $67.5M | $38.5M | $29.1M |
| Shareholders' equity | $1.52B | $864.8M | $453.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology